Established in 2019 by SK Inc., SK pharmteco is a global contract development and manufacturing organization (CDMO) with operations across the U.S., Europe, and South Korea. The company operates across three core business units: small molecules, peptides, and viral vectors, supporting biopharmaceutical partners across a range of therapeutic modalities.

SK pharmteco provides integrated development and manufacturing capabilities tailored to each modality. In small molecules and peptides, the company offers process development, scale-up, and commercial manufacturing, including expertise in high-potency APIs (HPAPIs), complex chemistries, and specialized peptide synthesis. In viral vectors, SK pharmteco supports lentiviral (LVV), adeno-associated viral (AAV), and adenovirus (AdV) vector development, GMP manufacturing, and technology transfer from early clinical stages through commercial supply.

With a global network of manufacturing and development sites, SK pharmteco emphasizes consistent quality, operational reliability, and regulatory compliance across all programs. Its platform is designed to support partners managing diverse or multi-modality pipelines, from established products to emerging therapies.